Test de dépistage par mammographie par tomosynthèse (TMIST)
MAC.22
NCT03233191
 Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
 HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Michel Archambault
514-338-2222 poste 3739
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Mary-Denise Dufour
418-541-1000 poste 2823
|
Étude de phase 3, ouverte, randomisée, comparant le gédatolisib associé au fulvestrant et avec ou sans palbociclib aux traitements standard chez des patientes atteintes d'un cancer du sein avancé HR-positif, HER2-négatif précédemment traitées avec un inhibiteur CDK4/6 en association avec traitement par inhibiteur non stéroïdien de l'aromatase
VIKTORIA-1
NCT05501886
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Mary-Denise Dufour
418-541-1000 poste 2823
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of arv-471 (pf-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study a (arv-471 in combination with abemaciclib)
TACTIVE-U
NCT05548127
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
ELISA
NCT04797299
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Caroline Hivon
450-466-5000 poste 2164
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of ARV-471 (PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study B (ARV-471 in combination with ribociclib)
TACTIVE-U
NCT05573555
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Alexandra Simard
418-541-1000 poste 3163
|
(EN) An interventional, open-label, randomized, multicenter phase 3 study of PF-07220060 plus fulvestrant compared to investigator's choice of therapy in participants over 18 years of age with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer whose disease progressed after prior CDK 4/6 inhibitor-based therapy
C4391022
NCT06105632
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
CAMBRIA-1
NCT05774951
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
(EN) A phase 3, randomized, open-label, multicenter trial of ARV-471 (PF-07850327) vs fulvestrant in participants with estrogen receptor-positive, her2-negative advanced breast cancer whose disease progressed after prior endocrine based treatment for advanced disease
VERITAC-2
NCT05654623
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
Groupe d'étude en oncologie du Québec